 Products |
|
| No.： | CPTA014 |
| Products： | Moxifloxacin |
| Synonyms： | (1’S,6’S)-1-Cyclopropyl-7-(2,8-diazabicyclo[4.3.0]non-8-yl)-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid |
| Cas No.： | 151096-09-2 |
| Molecular Formula： | C21H24FN3O4 |
| Molecular Weight： | 401.43 |
| Molecular Structure： |  |
| Moxifloxacin, the main dosage forms are tablets, injections. This product of gram-negative bacteria, gram-positive bacteria, mycoplasma, chlamydia and myelitis virus has good antibacterial activity. This product good oral absorption, and not easy the creation bears the medicine. Clinically for the treatment of infections of respiratory system, reproductive system, skin and soft tissue infection, etc. 【 indications 】 treatment of adults with upper respiratory tract and lower respiratory tract infections. Such as acute sinusitis, chronic bronchitis, acute onset, community-acquired pneumonia, and skin and soft tissue infections. 【 pharmacological toxicity 】 this product is the fourth generation quinolone kind of broad-spectrum antimicrobials, broad spectrum and antibacterial activity of 8 - methoxy fluoroquinolone antibiotic. Moxifloxacin in vitro show of gram-positive bacteria, gram-negative bacteria, anaerobic bacteria, acid resistant bacteria and atypical organisms such as mycoplasma, chlamydia, legionella bacteria and have broad spectrum antimicrobial activity. Antibacterial mechanism for the interference Ⅱ, Ⅳ topoisomerase. DNA topoisomerase is to control the complex topology and DNA |
|
|
